Zorubicin hydrochloride
Zorubicin hydrochloride (Rubidazon hydrochloride) is an anthracycline Antibiotic. Zorubicin hydrochloride exhibits activity against breast cancer, leukemia, and undifferentiated nasopharyngeal carcinoma. Zorubicin hydrochloride shows activity against undifferentiated nasopharyngeal carcinoma either as a monotherapy or in combination with Cisplatin (HY-17394). Zorubicin hydrochloride can be used in research related to breast cancer, leukemia, and undifferentiated nasopharyngeal carcinoma.
For research use only. We do not sell to patients.
- CAS No.: 36508-71-1
- Formula: C34H36ClN3O10
- Molecular Weight:682.12
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
All Antibiotic Isoforms
More
Biological Activity
Description
Chemical Information
-
CAS No. 36508-71-1
-
Molecular Weight 682.12
-
Formula C34H36ClN3O10
-
SMILES
OC1=C(C(C2=CC=CC(OC)=C2C3=O)=O)C3=C(O)C4=C1C[C@](/C(C)=N/NC(C5=CC=CC=C5)=O)(O)C[C@@H]4O[C@H]6C[C@@H]([C@@H]([C@@H](O6)C)O)N.Cl
-
Synonyms
Rubidazon hydrochloride; Rubidazone hydrochloride
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
Purity & Documentation
References
[1]. Bano N, et al. Drug Repurposing of Selected Antibiotics: An Emerging Approach in Cancer Drug Discovery. ACS omega. 2024 Jun 25;9(25):26762-26779. [Content Brief]
[2]. Jelić S, et al. Randomized study of zorubicin versus zorubicin-cisplatin in undifferentiated carcinoma of the nasopharynx (UCNT). Annals of oncology : official journal of the European Society for Medical Oncology. 1997 Aug;8(8):739-44. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Zorubicin hydrochloride Related Classifications
HY-183476 Related Classifications
Powered by Bioz